Business Description
Valeo Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA91915B1085
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | -1.17 | |||||
Debt-to-Equity | -1.4 | |||||
Debt-to-EBITDA | -5.76 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.62 | |||||
Beneish M-Score | -5.28 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 69.3 | |||||
3-Year EBITDA Growth Rate | -26.6 | |||||
3-Year EPS without NRI Growth Rate | -58.4 | |||||
3-Year FCF Growth Rate | -28.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47 | |||||
9-Day RSI | 41.07 | |||||
14-Day RSI | 39.45 | |||||
6-1 Month Momentum % | 10.34 | |||||
12-1 Month Momentum % | -68.63 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.49 | |||||
Quick Ratio | 0.3 | |||||
Cash Ratio | 0.19 | |||||
Days Inventory | 104.06 | |||||
Days Sales Outstanding | 35.75 | |||||
Days Payable | 61.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.5 | |||||
Shareholder Yield % | -135.07 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 21.38 | |||||
Operating Margin % | -33.58 | |||||
Net Margin % | -52.37 | |||||
FCF Margin % | -15.47 | |||||
ROA % | -63.68 | |||||
ROIC % | -59.91 | |||||
ROC (Joel Greenblatt) % | -207.28 | |||||
ROCE % | -63.82 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.16 | |||||
EV-to-EBIT | -4.76 | |||||
EV-to-EBITDA | -5.87 | |||||
EV-to-Revenue | 1.24 | |||||
EV-to-Forward-Revenue | 1.06 | |||||
EV-to-FCF | -7.86 | |||||
Earnings Yield (Greenblatt) % | -21.01 | |||||
FCF Yield % | -77.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Valeo Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 54.287 | ||
EPS (TTM) (C$) | -0.33 | ||
Beta | 1.54 | ||
Volatility % | 103.89 | ||
14-Day RSI | 39.45 | ||
14-Day ATR (C$) | 0.014038 | ||
20-Day SMA (C$) | 0.13575 | ||
12-1 Month Momentum % | -68.63 | ||
52-Week Range (C$) | 0.06 - 0.52 | ||
Shares Outstanding (Mil) | 98.66 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Valeo Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Valeo Pharma Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Valeo Pharma Inc Frequently Asked Questions
What is Valeo Pharma Inc(TSX:VPH)'s stock price today?
When is next earnings date of Valeo Pharma Inc(TSX:VPH)?
Does Valeo Pharma Inc(TSX:VPH) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |